Expand IGC Menu
IGC MENU

IGC Latest Press Releases

-- August 17, 2026 --

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure ACCESS Newswire 8:30 AM

-- August 11, 2026 --

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout ACCESS Newswire 8:30 AM

-- July 29, 2026 --

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign ACCESS Newswire 8:30 AM

-- July 9, 2026 --

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS Newswire 9:00 AM

-- July 7, 2026 --

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company ACCESS Newswire 9:00 AM

-- June 23, 2026 --

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS Newswire 8:30 AM

-- June 11, 2026 --

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis ACCESS Newswire 8:30 AM

-- June 9, 2026 --

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts ACCESS Newswire 8:30 AM

-- June 2, 2026 --

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis ACCESS Newswire 8:30 AM

-- May 19, 2026 --

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment ACCESS Newswire 5:30 PM

-- May 15, 2026 --

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference ACCESS Newswire 8:00 AM

-- April 28, 2026 --

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase ACCESS Newswire 12:15 PM

-- April 22, 2026 --

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion ACCESS Newswire 8:30 AM

-- April 20, 2026 --

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia ACCESS Newswire 8:30 AM

-- April 14, 2026 --

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout ACCESS Newswire 8:30 AM

-- April 8, 2026 --

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts ACCESS Newswire 12:45 PM

-- April 7, 2026 --

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease ACCESS Newswire 8:00 AM

-- March 30, 2026 --

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness ACCESS Newswire 8:00 AM
Market Data Delayed 15 Minutes